Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DANAZOL

All products: general benefit

Cyclomen · DIN 02018160 · 200mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Cyclomen · DIN 02018160 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2009-02-06 · brand CYCLOMEN · ATC G03XA01 DANAZOL · form Capsule · route Oral · ingredients DANAZOL 200 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Cyclomen: Formulary list price $2.5425/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.5425 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14747 · Verify on the e-Formulary ↗ (DIN 02018160)

Source record
DIN 02018160: Cyclomen Raw flags: sec3=Y Item: 680800015; group id 722; item number 1783; lccId None; manufacturer id SAV Source form: Cap; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $2.5425; ministry $2.5425 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02018160 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14747
Shortage status: resolved shortage (ended 2020-02-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02018160
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:08 Androgens) and how they are covered

Matched class: 68:08 Androgens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 68:08 Androgens

TESTOSTERONE

· 5 products · Limited Use, codes 397 · strengths: 1% · 2.5g Foil Packet, 5.0g Foil Packet, Top Gel-5g Pk

TESTOSTERONE CYPIONATE

· 2 products · Listed, not a benefit (1), Limited Use, codes 397 (1) · strengths: 100mg/mL · Oily Inj Sol-10mL Pk

TESTOSTERONE ENANTHATE

· 2 products · Listed, not a benefit (1), Limited Use, codes 397 (1) · strengths: 1000mg/5mL · Oily Inj Sol-5mL Pk

TESTOSTERONE UNDECANOATE

· 2 products · Listed, not a benefit (1), Limited Use, codes 397 (1) · strengths: 40mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:08
Full class listing Related classes: 68:04 Corticosteroids, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Endometriosis: Cyclomen (danazol) is indicated for the treatment of endometriosis associated symptoms and/or to reduce the extent of endometriotic foci. Cyclomen may be used either in conjunction with surgery or, as sole hormonal therapy, in patients not responding to other treatments. Benign Fibrocystic Breast Disease: Cyclomen (danazol) is indicated for the symptomatic relief of severe pain and tenderness associated with fibrocystic disease of the breast. Cyclomen should be used in those patients who do not obtain adequate relief through other therapeutic measures or in whom such measures are otherwise inadvisable. Carcinoma of the breast should be excluded prior to commencing treatment. The treatment course should be limited to three to six months maximum. https://pdf.hres.ca/dpd_pm/00039595.PDF PM date: May 18, 2017 Source product: CYCLOMEN; DIN 02018152; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.